...
首页> 外文期刊>Biochemical and Biophysical Research Communications >Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway
【24h】

Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway

机译:miR-223和miR-19a的下调诱导分化并促进通过RUNX2 / Twist-Rankl途径募集骨细胞瘤中骨细胞瘤的募集

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Giant-cell tumor (GCT) of the bone is an invasiveness and high recurrent bone tumor that is considered borderline or potentially malignant. To explore the molecular mechanism leading to bone destruction and identify novel targets for treatment, we conducted silencing of miR-223 and miR-19a in stromal giant cells and identified TWIST and Runx2 as their target genes. We investigated the impact of these microRNAs and their target genes on stromal giant cells that promote the differentiation of monocyte/macrophages into osteoclast cells and recruitment to the bone microenvironment, which in turn enhances the bone destruction capacity of GCT. MiR-223 and miR-19a were found to regulate the expression of TWIST and Runx2, influence the RANKL-RANK pathway and the expression of MCP-1, and finally regulate the pathophysiological process of osteolytic bone destruction. Our results indicate that re-expression of miR-223 and miR-19a induces an inhibitory effect on the bone destruction capacity of GCT, suggesting that re-expression of miR-223 and miR-19a can be a novel strategy for the treatment of GCT. (C) 2018 Published by Elsevier Inc.
机译:骨的巨细胞肿瘤(GCT)是一种侵袭性和高复发性骨肿瘤,被认为是濒临突线或潜在恶性的。为了探讨导致骨破坏和识别治疗靶标的分子机制,我们在基质巨细胞中沉默miR-223和miR-19a,并确定了捻和润润,作为其靶基因。我们调查了这些MicroRNA和它们的靶基因对基质巨细胞的影响,促进单核细胞/巨噬细胞分化为骨细胞细胞并募集到骨髓微环境,这反过来提高了GCT的骨破坏能力。发现miR-223和miR-19a调节扭曲和runx2的表达,影响RANKL-RANK途径和MCP-1的表达,最终调节骨溶骨破坏的病理生理过程。我们的结果表明,MIR-223和MIR-19A的重新表达诱导对GCT的骨破坏能力的抑制作用,表明MIR-223和MIR-19A的再表达可以是GCT治疗的新策略。 (c)2018年由elsevier公司发布

著录项

  • 来源
  • 作者单位

    Shenzhen Longhua Dist Peoples Hosp Dept Hand Surg Shenzhen 518109 Peoples R China;

    Fudan Univ Huashan Hosp Dept Hand Surg 12 Wulumuqi Middle Rd Shanghai 200040 Peoples R China;

    East China Normal Univ Shanghai Engn Res Ctr Mol Therapeut &

    New Drug De Coll Chem &

    Mol Engn;

    Zhejiang Univ Sch Med Sir Run Run Shaw Hosp Dept Orthoped Hangzhou 310016 Zhejiang Peoples R;

    Wenzhou Med Univ Hosp Taizhou 1 Dept Hand Surg Taizhou 318020 Zhejiang Peoples R China;

    Second Mil Med Univ Changzheng Hosp Dept Joint Surg &

    Orthoped Sports Med Shanghai 200003;

    Shanghai Jiao Tong Univ Shanghai Inst Immunol Inst Med Sci Sch Med Shanghai 200031 Peoples R;

    Fudan Univ Huashan Hosp Dept Hand Surg 12 Wulumuqi Middle Rd Shanghai 200040 Peoples R China;

    Tongji Univ Shanghai Peoples Hosp 10 Cent Lab Med Res Sch Med Middle 301 Yanchang Rd Shanghai;

    Fudan Univ Huashan Hosp Dept Hand Surg 12 Wulumuqi Middle Rd Shanghai 200040 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

    GCT; miR-223; miR-19a; Osteoclast cells;

    机译:GCT;miR-223;mir-19a;骨骨糖细胞;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号